Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Macular Degeneration Treatment Market Grown from 2024 to 2025?

The market for macular degeneration treatment has seen significant growth in previous years. The expansion is expected to continue, with market size predicted to increase from $11.05 billion in 2024 to $12.42 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.4%. Several factors contribute to the growth witnessed during the historic period, including an aging population, changes in lifestyle, scarcity of treatment alternatives, heightened awareness, and improvements in healthcare infrastructure.

What Growth Rate Is Anticipated for the Macular Degeneration Treatment Market in the Coming Years?

The market for treatments for macular degeneration is projected to experience swift expansion in the coming years, with an estimated value of $19.06 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.3%. The anticipated growth during the forecast period can be credited to advancements in scientific research, an increase in healthcare spending, escalating incidence rates, customized medicinal treatments, and worldwide initiatives toward vision health. Key trends for this period encompass focus on neuroprotective and regenerative treatments, the broadening of telemedicine and distance monitoring, personalization in medicine, exploration of stem cell therapies, and patient-centric initiatives for increasing awareness and education.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

Who Are the Leading Companies in the Macular Degeneration Treatment Market?

Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.

What Are the Key Drivers of the Macular Degeneration Treatment Market?

The macular degeneration treatment market is projected to grow owing to the escalating prevalence of retinal disorders. These disorders can impair the essential tissue and disrupt how visual data is processed, resulting in either warped or non-existent vision. As an example, the American Academy of Ophthalmology has forecasted that by 2050, roughly 7.32 million U.S citizens will be suffering from primary open-angle glaucoma, a broad term for a range of eye-related conditions. The majority of those affected will be those between the ages of 70 and 79 (32%), women (50%), and Hispanics (50%); the most substantial demographic portion being Hispanic males. Hence, the surge in retinal disorders incidence is fueling the expansion of the macular degeneration treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp

What Are the Key Market Segments in the Macular Degeneration Treatment Industry?

The macular degeneration treatment market covered in this report is segmented –

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD

2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals

3) By Route of Administration: Oral, Injectable, Other Route of Administration

4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Subsegments:

1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments

2) By Intermediate AMD: Anti-VEGF Injections, Photodynamic Therapy

3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

What Are the Latest Trends in the Macular Degeneration Treatment Market?

Key firms engaged in the macular degeneration treatment industry are focusing on creating biosimilars to treat age-related macular degeneration (AMD) in order to enhance access to effective treatment. Biosimilars are biological medication products that are almost identical to an already approved reference product, and there are no clinically significant differences related to safety, purity, or potency. For instance, Biocon Biologics Ltd, an Indian company, and Samsung Bioepis Co. Ltd, from South Korea, received FDA approvals for Yesafili and Opuviz, two new biosimilars, in May 2024. The biosimilars both block vascular endothelial growth factor (VEGF), which causes unusual blood vessel growth in the eye, thereby preventing vision loss linked to conditions like AMD and diabetic retinopathy. The approval process by the FDA included comparative analysis that showed no notable differences in efficacy or safety between Yesafili and Opuviz compared to Eylea. Such studies conducted thorough examinations of the biosimilars’ pharmacokinetics and immunogenicity.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

What Are the Key Regional Markets in the Macular Degeneration Treatment Industry?

North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5799

This Report Delivers Insight On:

1. How big is the macular degeneration treatment market, and how is it changing globally?

2. Who are the major companies in the macular degeneration treatment market, and how are they performing?

3. What are the key opportunities and risks in the macular degeneration treatment market right now?

4. Which products or customer segments are growing the most in the macular degeneration treatment market?

5. What factors are helping or slowing down the growth of the macular degeneration treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model